Scribe Therapeutics
Scribe Therapeutics is a clinical-stage biotech developing CRISPR-based genetic medicines using proprietary X-Editor (XE) and ELXR platforms, initially targeting cardiometabolic disease with single-dose, durable therapies delivered via lipid nanoparticles.
- Company typePrivate
- Founded2017
- HeadquartersAlameda, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Scribe Therapeutics does
Scribe Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Alameda, California, that engineers CRISPR-based genetic medicines for cardiometabolic and other high-burden diseases. The company's technology foundation consists of two proprietary platforms built on engineered CasX-derived proteins: X-Editor (XE), a gene editing platform that delivers >100x higher activity than naturally occurring CasX with no detectable off-targets at >75% liver editing in NHPs, and ELXR (Epigenetic Long-Term X-Repressor), a nuclease-inactivated system fused to epigenetic effector domains that durably silences gene expression without permanently altering DNA, supported by allosteric regulation. An internal AI tool, DeepXE, reduces guide RNA screening burden by 50%. The lead wholly-owned asset, STX-1150, is an ELXR-based therapy delivered via lipid nanoparticles to silence PCSK9 in the liver for durable LDL-C reduction; it received Australian TGA clearance in May 2026 and entered a first-in-human Phase 1 study in Australia and New Zealand. Two additional preclinical wholly-owned programs (STX-1200 targeting LPA for Lp(a) lowering and STX-1400 targeting APOC3 for triglyceride reduction) are funded by a >$25M CIRM award from June 2026.
Scribe's business model is a partnership-driven biotech model: the company monetizes its XE and ELXR platforms through co-development and licensing deals with major pharmaceutical companies rather than through direct product sales. Active partners include Eli Lilly (via Prevail Therapeutics) for neurological and neuromuscular diseases (>$1.5B in potential milestones plus tiered royalties), Sanofi for in vivo sickle cell and genomic diseases (>$1.2B in potential milestones) and for ex vivo NK cell oncology therapies (>$1B potential), and Biogen for ALS. Scribe retains co-funding and co-promotion/profit-sharing options on select US programs, and the company reported $51.2M in collaboration revenue for FY2025. The company is privately held, backed by a16z, OrbiMed, Avoro Ventures, Wellington Management, Perceptive Advisors, Menlo Ventures, T. Rowe Price, and RaCapital, and filed for a Nasdaq IPO under ticker SCTX in July 2026 targeting up to $75M. Scientific leadership is anchored by co-founder Jennifer Doudna (CRISPR co-discoverer and Nobel laureate) and a co-founding team of Benjamin Oakes (CEO), David Savage, and Brett Staahl, all with deep UC Berkeley roots.
Scribe Therapeutics firmographics
Firmographics- Name
- Scribe Therapeutics
- Legal name
- Scribe Therapeutics
- Website
- https://scribetx.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Scribe Therapeutics is a clinical-stage biotech developing CRISPR-based genetic medicines using proprietary X-Editor (XE) and ELXR platforms, initially targeting cardiometabolic disease with single-dose, durable therapies delivered via lipid nanoparticles.
- Ownership category
- akta.pro rank
Scribe Therapeutics industry classification
Industry- Product category
- Genetic Medicines
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
- akta.pro secondary industries
- Neurology/CNS Gene Therapies (HLAAACAH), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Scribe Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Alameda
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Scribe Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Strategic Collaboration Payments: Upfront payments, equity investments, R&D funding, milestone payments, and tiered royalties from pharmaceutical partnerships with Sanofi and Eli Lilly/Prevail. Reported $51.2M in collaboration revenue for FY2025.
- Government Grants: CIRM awards ($25M+) for preclinical development of cardiometabolic gene editing programs STX-1200 and STX-1400.
- IPO Proceeds: Planned Nasdaq IPO targeting up to $75 million to fund clinical development of cardiometabolic pipeline.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Scribe Therapeutics product offering
Product offeringCore offering
Scribe Therapeutics is a clinical-stage biotechnology company that engineers CRISPR-based genetic medicines for cardiometabolic disease. The company develops therapeutic candidates using two proprietary platforms—X-Editor (XE), an engineered CRISPR-CasX-based gene editing system, and ELXR (Epigenetic Long-Term X-Repressor), a reversible epigenetic silencing technology—supported by the DeepXE AI design platform for guide RNA optimization. Lead candidate STX-1150 targets PCSK9 for LDL-C lowering and is in Phase 1 clinical trials.
Product overview
Scribe Therapeutics is a clinical-stage biotechnology company developing CRISPR-based genetic medicines for cardiometabolic disease. The company offers two core technology platforms: X-Editor (XE) for gene editing and Epigenetic Long-Term X-Repressor (ELXR) for epigenetic silencing. The proprietary CRISPR by Design approach engineers bacterial immune systems into therapeutically relevant genome editing tools. The clinical-stage pipeline includes STX-1150 (PCSK9 silencing for LDL-C lowering), while preclinical programs include STX-1200 (LPA targeting for Lp(a) lowering) and STX-1400 (APOC3 targeting for triglyceride lowering). The company has strategic collaborations with Sanofi and Eli Lilly/Prevail Therapeutics for additional therapeutic programs.
Differentiator
Problem solved
Functional benefit
Products and services
- STX-1150 A clinical-stage liver-targeted CRISPR-based epigenetic silencing therapy that uses ELXR technology delivered via lipid nanoparticles to durably reduce LDL-C by silencing the PCSK9 gene without permanently altering DNA. Designed for adults with elevated LDL-C at increased cardiovascular risk.
- STX-1200 A preclinical CRISPR-based gene editing therapy that uses X-Editor (XE) technology to target the LPA gene to reduce lipoprotein(a) [Lp(a)] for treatment and prevention of atherosclerotic cardiovascular disease in patients with genetically elevated Lp(a).
- STX-1400 A preclinical CRISPR-based gene editing therapy using X-Editor (XE) technology that targets APOC3 to lower triglyceride-rich lipoproteins for addressing acute pancreatitis in triglyceride-driven diseases such as familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia syndrome (MCS).
- X-Editor (XE) Platform A proprietary CRISPR-based gene editing technology using a staggered DNA cleavage mechanism with >100-fold higher editing activity than naturally occurring CasX. Supports gene knock-out, knock-down, knock-in, exon skipping, and genetic excision. Licensed to pharmaceutical partners for therapeutic development.
- ELXR (Epigenetic Long-Term X-Repressor) Platform A proprietary CRISPR-based epigenetic silencing technology built on nuclease-inactivated engineered CasX fused to epigenetic effector domains with allosteric regulation for enhanced specificity. Enables durable yet reversible gene silencing without altering DNA. Licensed to pharmaceutical partners for therapeutic development.
- DeepXE AI Design Platform
Quantifiable outcome
- Single dose of STX-1150 achieved >50% LDL-C reduction sustained for >22 months in non-human primates
- +5 more outcomes
Companies that use Scribe Therapeutics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Scribe Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Scribe Therapeutics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and flagship.
- California Institute for Regenerative Medicine (CIRM)coreCIRM awarded Scribe more than $25 million across two preclinical programs (STX-1200 for Lp(a) lowering and STX-1400 for triglyceride reduction) through its Preclinical Development Program to advance CRISPR-based gene editing therapies toward clinical trials in California.
- SanofiflagshipExpanded collaboration for in vivo genetic medicines targeting sickle cell disease and other genomic diseases using Scribe's CRISPR XE technologies with Sanofi's non-viral delivery. Scribe receives $40M upfront with potential milestones exceeding $1.2B and tiered royalties (high single digits to low double digits). Scribe has co-promotion/profit sharing option on one US program. Sanofi also exercised option for second in vivo target in January 2024. Companies achieved first success milestone in January 2025.
- Eli Lilly (Prevail Therapeutics)flagshipStrategic collaboration to develop in vivo CRISPR-based genetic medicines for neurological and neuromuscular diseases. Scribe grants exclusive rights to its CRISPR X-Editing technologies for specified targets. Scribe receives $75M upfront and equity investment, with potential milestones exceeding $1.5B and tiered royalties into low double-digits. Scribe retains option to co-fund and share profits on one US program. Two success milestones achieved as of February 2026.
- Sanofi (NK Cell Therapy)coreInitial collaboration granting Sanofi non-exclusive license to CRISPR by Design platform and CasX-Editor technology for developing engineered NK cell therapies for multiple oncology indications. Scribe receives $25M upfront with potential milestones exceeding $1B plus tiered royalties.
- Acuitas TherapeuticscoreLicensor of liver-tropic lipid nanoparticle (LNP) delivery technology used to encapsulate STX-1150's mRNA encoding ELXR and guide RNA for liver-targeted PCSK9 targeting. LNP delivery enables efficient hepatocyte uptake for epigenetic silencing therapy.
- BiogencoreResearch collaboration to develop CRISPR-based therapies for ALS. Biogen exercised option for an additional disease target in 2025, expanding the collaboration. Focus on neurological disorders with potential for in vivo CNS editing using Scribe's XE technology.
- Innovative Genomics InstitutecoreCo-founded by Nobel laureate Jennifer Doudna; Scribe was co-founded based on science from this institute. Provides scientific collaboration and academic partnership.
- UC BerkeleycoreAcademic institution where co-founders Jennifer Doudna, David Savage, and Benjamin Oakes conducted foundational CRISPR research. Primary source of Scribe's core technology and scientific talent.
Scale indicators11 records
Recent moves7 records
Expansion highlights7 records
Scribe Therapeutics competitors and assessment
Company assessmentDirect peers
- Verve Therapeutics: Clinical-stage biotech developing in vivo gene editing medicines for cardiovascular disease, including a lead PCSK9 program (VERVE-101) targeting the same LDL-C indication as Scribe's STX-1150. Most directly comparable peer given shared indication, base-editing/in vivo editing approach, and partnership model.
- Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company developing both in vivo (liver, including transthyretin amyloidosis) and ex vivo (oncology) programs. Closely comparable platform stage and modality mix, with ongoing partnerships with Regeneron and Novartis.
- CRISPR Therapeutics: First company to commercialize a CRISPR-based therapy (Casgevy for sickle cell disease) via partnership with Vertex. Directly comparable in vivo and ex vivo pipeline, with overlapping sickle cell and cardiometabolic programs.
- Editas Medicine: Clinical-stage gene editing company developing CRISPR-based medicines, including Casgevy co-developer with a sickle cell program overlapping Scribe's Sanofi-partnered indication. Comparable platform orientation and stage.
- Beam Therapeutics: Clinical-stage biotech developing base editing medicines, including cardiovascular programs (e.g., BEAM-301 for GSD1a) and a partnered sickle cell program with Pfizer. Highly comparable modality (precision gene editing) and target overlap.
- Prime Medicine: Clinical-stage company developing prime editing therapies with both wholly-owned and partnered programs. Comparable platform-stage CRISPR-derived modality, with overlap in chronic and rare disease indications.
Broad incumbents
- Sangamo Therapeutics: Pioneer in genome engineering (zinc finger, AAV-based) with clinical-stage programs in cardiometabolic and rare diseases including a partnered PCSK9 program with Eli Lilly. Broader incumbent in the gene editing/genome engineering space with overlap in cardiovascular targets.
Emerging players
- Caribou Biosciences: Clinical-stage CRISPR genome editing company with allogeneic CAR-T and iPSC-derived NK cell programs. Partial overlap with Scribe's ex vivo NK cell collaboration with Sanofi, and similar platform-stage orientation.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Scribe Therapeutics social profiles
Digital presenceScribe Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scribe Therapeutics leadership team
Management profileNumber of profiles
Profiles13 records
Scribe Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scribe Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scribe Therapeutics
What does Scribe Therapeutics do?
Scribe Therapeutics is a clinical-stage biotechnology company that engineers CRISPR-based genetic medicines for cardiometabolic disease. The company develops therapeutic candidates using two proprietary platforms—X-Editor (XE), an engineered CRISPR-CasX-based gene editing system, and ELXR (Epigenetic Long-Term X-Repressor), a reversible epigenetic silencing technology—supported by the DeepXE AI design platform for guide RNA optimization. Lead candidate STX-1150 targets PCSK9 for LDL-C lowering and is in Phase 1 clinical trials.
Is Scribe Therapeutics a public or private company?
Scribe Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Scribe Therapeutics founded?
Scribe Therapeutics was founded in 2017. It employs 51 to 100 people.
Where is Scribe Therapeutics based?
Scribe Therapeutics is headquartered in Alameda, United States, in the North America region.
How does Scribe Therapeutics make money?
Three revenue lines are on record. Strategic Collaboration Payments are the primary driver. The others are government Grants and IPO Proceeds.
Who are Scribe Therapeutics's main competitors?
Direct peers on record are Verve Therapeutics, Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, Beam Therapeutics and Prime Medicine. Sangamo Therapeutics is listed as a broad incumbent. Caribou Biosciences is listed as an emerging player.
Does Scribe Therapeutics have an API?
No public API is recorded for Scribe Therapeutics.
What industry is Scribe Therapeutics in?
Scribe Therapeutics's product category is Genetic Medicines. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 2834.